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A
lthough leprosy is no longer a health problem in 
developed countries, it continues to affect millions 
of people in large parts of Asia, Africa, and Latin 
America. Effective chemotherapeutic treatments are available 
that have reduced the global disease burden dramatically, 
but there remain important challenges to ﬁ  ghting and 
controlling the disease.
Clinical Features
Leprosy is a chronic infection of the skin and peripheral 
nerves, caused by the obligate intracellular bacterium 
Mycobacterium leprae, the “Hansen’s Bacillus” (Figure 1) [1]. 
Mainly transmitted by the aerosol spread of nasal secretions, 
the ﬁ  rst symptoms may appear after an incubation period 
(usually ﬁ  ve to ten years) following infection, and the onset is 
intermittent and gradual.
Skin lesions and nerve damage are the main clinical 
features of the disease. Blindness may develop, resulting 
either from destruction of peripheral nerves within ocular 
tissues or from direct bacillary corneal invasion. Some 
patients—particularly those with lepromatous leprosy 
(see below)—may be affected by bacillary inﬁ  ltration 
into the mucosa of the upper respiratory tract, bones, 
and testes [2]. Diagnosis of leprosy is mostly clinical and 
symptomatic, based on the presence of a few cardinal signs: 
hypopigmented or reddish-copper patches with deﬁ  nite 
sensory loss, with or without thickened nerves, and positive 
skin smears [3].
The disease occurs in a wide spectrum of forms, which stem 
from the varying host immune response to the pathogen. 
Individuals with tuberculoid leprosy display a strong cell-
based immune response that controls bacterial proliferation 
and lesions, whereas patients with lepromatous leprosy lack 
speciﬁ  c cellular immunity, ending up with high mycobacterial 
loads and severe clinical manifestations. Most patients have 
borderline forms. After the age of puberty, leprosy has a 
male to female ratio of 1.5–2.0 to 1. Britton and Lockwood 
have pointed out that this male preponderance is real—it is 
not related to underdiagnosis in women, although in some 
countries it is accentuated by delayed presentation by female 
patients, which results in higher rates of deformity [2].
The impairment of nerve function is due both to 
involvement of nerves by the primary infection, and to the 
acute immunological phenomena known as reversal reactions 
or type-1 leprosy reactions. These reactions occur in a third 
of patients with borderline forms of disease, are caused by 
spontaneous increases in T-cell reactivity to mycobacterial 
antigens, and are associated with the inﬁ  ltration of 
interferon γ and TNFα-secreting CD4-positive lymphocytes 
in skin lesions and nerves, resulting in oedema and painful 
inﬂ  ammation [2]. Sensory loss makes affected patients prone 
to inadvertent injury, leading to severe disabilities and visible 
deformities (Figure 2).
Burden of Disease and Disability
Given the lifelong effects of nerve damage and its consequent 
disabilities—which often affect very young people—and the 
pressure this burden of disease and disability poses on fragile 
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Figure 1. Photomicrograph of Mycobacterium leprae Taken from a 
Leprosy Skin Lesion 
(Photo: Centers for Disease Control and Prevention)
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medical systems, the prevention, detection, and management 
of nerve function impairment are pivotal to all leprosy-control 
programmes [2].
Foot ulcers alone, for example, which are common in 
anaesthetic feet, can pose a huge burden on medical services. 
The social consequences for those affected with leprosy and 
for their families can be devastating. Stigma, community 
rejection, loss of employment, and sometimes forced 
isolation are still prevalent in both endemic and non-endemic 
countries [4].
The Biology of M. Leprae
One of the oldest recorded diseases [5], leprosy was also 
the ﬁ  rst human pathogenic condition of bacterial origin 
for which the causative agent was identiﬁ  ed. Despite these 
historical records, our knowledge of the biology of M. leprae 
has lagged behind, in good part because it cannot be grown 
in culture.
The full sequencing of the M. leprae genome, completed 
in 2001, has created possibilities for the development of 
new diagnostic tests and treatments for leprosy [6]. Analysis 
of the M. leprae genome has revealed that it contains fewer 
than half the functional genes of its closest relative, the 
tubercule bacillus M. tuberculosis [6,7]. This “minimal gene 
set”, the result of extensive gene deletion and decay that have 
eliminated many key metabolic pathways, renders the leprosy 
mycobacterium extremely slow in replicating and forces it to 
an intracellular existence.
In some areas such as the Middle East and Europe, leprosy 
declined after the late medieval period. One theory for the 
decline is that it was related to the increasing prevalence 
of tuberculosis—cross-immunity may have protected 
patients with tuberculosis from developing leprosy, or the 
compromised immunological status of patients with leprosy 
may have rendered them more susceptible to underlying 
latent tuberculosis infection, which resulted in increased 
mortality [8].
The Global Elimination Campaign
Leprosy now occurs mainly in resource-poor countries in 
tropical and warm temperate regions. Contrary to a widely 
believed myth, nowadays leprosy is a fully curable disease. 
A multidrug therapy (MDT) based on the combination of 
the antibiotics dapsone, rifampicin, and clofazimine was 
introduced in 1982 after dapsone-resistant strains appeared 
and spread. MDT proved highly efﬁ  cacious in killing the 
bacteria without inducing resistance, although the optimal 
length of treatment and associated relapse rates are still 
controversial [2].
With such a powerful weapon at hand, a massive 
international effort was launched to eradicate leprosy 
worldwide. In 1991, the World Health Assembly adopted the 
target of “elimination of leprosy as a public health problem by 
the year 2000”. Elimination was deﬁ  ned as a reduction in the 
prevalence of patients with leprosy receiving antimicrobial 
therapy at a given time to less than 1 per 10,000 population. It 
was expected that by reducing the prevalence to this level, the 
transmission of M. leprae would be interrupted, leading to the 
gradual extinction of the disease. Since its introduction, some 
13 to 14 million people have been cured with MDT (made 
available free of cost by the Sasakawa Foundation and then 
by Novartis), and full control of the disease (as assessed by 
prevalence rate) has been ofﬁ  cially achieved in 112 of the 122 
countries where leprosy was endemic in 1985.
The Final Push
The World Health Organization (WHO) dubbed the 
ambitious project “the ﬁ  nal push to eliminate leprosy”. The 
strategy behind the slogan involves expanding MDT services 
to all health facilities and making leprosy diagnosis available, 
training health workers to diagnose and treat leprosy, 
promoting leprosy awareness and encouraging people to seek 
and continue treatment [9]. However, despite the impressive 
results obtained so far by the elimination campaign, this is 
still a work in progress.
According to the last WHO report (for 2003), ten countries 
in Africa, Asia, and Latin America still show prevalence rates 
above the selected threshold [10]. Topping this short list is 
a group of six endemic countries that together account for 
83% of the leprosy cases registered worldwide: India, Brazil, 
Madagascar, Mozambique, Nepal, and Tanzania. According 
to WHO, in 2004 the number of patients with leprosy 
worldwide was 457,792 [11].
Worryingly, whereas prevalence ﬁ  gures have fallen steadily 
in the last two decades, the annual rate of new cases did 
not follow a comparable trend—this rate has remained 
essentially unchanged over the past ten years. Indeed, the 
number of new cases detected during 1994 was 560,646, 
increasing to 804,357 in 1998, then falling again to 513,798 
in 2003 [10,11]. On the basis of available information, 
WHO considers the “global target of leprosy elimination” as 
reached, and has shifted the strategy to the national level, 
for which elimination has been rescheduled for the end of 
2005 [10]. In its plans, WHO estimates that eight out of the 
remaining ten countries will reach the new target, while India 
and Brazil will probably need additional time.
The key constraints to eliminating leprosy in those 
countries that lag behind the elimination campaign vary 
greatly from country to country. In some leprosy-endemic 
countries (such as Madagascar, Mozambique, Nepal, and 
Tanzania), access to many health facilities is extremely poor 
because of difﬁ  cult terrain, displacement of populations in 
remote areas, or for security reasons [10]. In other countries, 
such as Brazil, important problems arise from the very 
centralised structure of the leprosy programme, and from its 
poor integration with general health services [10]. To deal 
with these very different scenarios, the strategies identiﬁ  ed by 
WHO vary accordingly, proposing in some cases the complete 
restructuring of the national leprosy programmes [10].
A New Strategy for an Uncertain Future
So what will happen after 2005? Leprologists and people 
involved in disease control fear that once leprosy is declared 
“eliminated as a public health problem”, the future of anti-
leprosy services and of leprosy workers and researchers 
will be at high risk [12,13]. Elimination is not eradication, 
many warn, and it must be clear to everyone that leprosy will 
continue to exist even in areas where the “elimination goal” 
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has ofﬁ  cially been reached. The term elimination itself makes 
people think the problem is over, say critics of the WHO 
policy, which can have detrimental effects on the future 
commitment of governments to sustain control activities, 
making it at the same time difﬁ  cult for leprosy NGOs and 
scientists to raise funds for ﬁ  eld and lab work.
Others believe that the concept of elimination itself, and 
the choice of prevalence as an indicator to measure the 
progress of the WHO-orchestrated campaign, are scientiﬁ  cally 
devoid of signiﬁ  cance—as is the 2005 deadline. “As a matter 
of fact, the wrong indicator has been selected to reﬂ  ect the 
progress toward elimination of leprosy,” says Piet Feenstra at 
the Royal Tropical Institute of Amsterdam (Amsterdam, The 
Netherlands), remarking that new-case detection and the 
proportion of children among new cases would serve much 
better to monitor the real disease status.
The International Leprosy Association’s Technical 
Forum has also noted that the expectation that reduction of 
prevalence to very low levels would lead to a reduction of the 
incidence within a few years was overoptimistic, as there was 
little evidence to support this hypothesis [14]. Since patients 
are only registered while they are on medication, prevalence 
ﬁ  gures by WHO standards vary depending on how long 
treatment lasts. “The decrease of prevalence is attributable 
primarily to the cleaning of the registers (discharge of 
cured or defaulting patients), to shortening the duration of 
treatment and, in some countries, to improved diagnostic 
accuracy, and is not a consequence of reduction of the 
transmission of Mycobacterium leprae,” Feenstra says.
“I believe there is probably a lot more leprosy in the world 
than the World Health Organization currently accepts,” 
agrees Helen Donoghue, a leprosy researcher at the 
Windeyer Institute of Medical Sciences (London, United 
Kingdom). The political implications of the “elimination 
goal”, and the way it was enforced by WHO, have also been 
questioned. “Over the last years, the elimination target has 
more and more become a political target [rather] than an 
epidemiological or program quality target,” says Feenstra. 
“For many, the indicator—the prevalence of patients 
registered for treatment—has become the goal in itself, and 
the actual goal—reduction of the leprosy transmission and 
incidence—has practically got out of sight”. Furthermore, 
the ﬁ  xing of numerical targets may put excessive pressure on 
national leprosy programme managers, discouraging them 
from actively working to detect new cases, which in turn could 
jeopardise the country’s elimination status.
Cracks in the Coalition
Another cause for serious concern is that the coalition 
that stands against leprosy is not as solid as it should be. In 
1999, the Global Alliance for the Elimination of Leprosy 
(GAEL) was formed to inject new energy into the elimination 
campaign, bringing together WHO, the governments of the 
major endemic countries, the Japanese Nippon Foundation, 
the Novartis Foundation for Sustainable Development, the 
Danish Development Cooperation Agency (Danida), and the 
International Federation of Anti-Leprosy Associations (ILEP). 
Quite soon, major contrasts emerged between some of the 
GAEL partners, namely between WHO and ILEP, who always 
remained critical of the “elimination”-focussed strategy. The 
clash was so strong that ILEP was expelled from the alliance 
at the end of 2001.
Later on, probably in response to the increasing pressure 
to achieve leprosy control, WHO invited an independent 
team of experts led by Richard Skolnik, former Director 
of the Center for Global Health at George Washington 
University (Washington, District of Columbia, United States), 
to evaluate the GAEL. The evaluation report, published in 
2003, recommends that WHO should take leprosy activities 
beyond 2005, dropping the “elimination” goal in favour of 
“an explicitly broad-based approach to the control of leprosy, 
the avoidance of nerve damage, and the rehabilitation of 
those in need” [15]. The team also explicitly called for the 
reconstitution of a reﬁ  ned alliance, where “collaborators will 
have to work more openly, collegially, and inclusively” [15].
There are signs that this new alliance is emerging. 
“The process of dialogue and collaboration with WHO 
headquarters in Geneva has already been reestablished and is 
improving constantly,” says Sunil Deepak, president of ILEP 
and medical director of the Italian leprosy NGO Associazione 
Italiana Amici di Raoul Follerau (AIFO). Deepak adds, 
“We are very optimistic about further strengthening of 
this collaboration”. Feenstra conﬁ  rms that stakeholders 
are exploring new ways of dialogue. “WHO is currently, in 
collaboration with its partners, ILEP, The Nippon Foundation 
and Novartis, developing a new strategy for the period 2006–
2010 for sustaining quality leprosy control activities,” he says 
(also see [16]).
A “Post-Elimination” Strategy
John Porter from the London School of Hygiene and 
Tropical Medicine (London, United Kingdom) recently 
argued that in order to make sure “the disease does not 
go underground”, the “elimination” strategy must be 
swiftly converted to a “post-elimination” strategy [12]. As 
recommended by many leprosy experts, this post-elimination 
DOI: 10.1371/journal.pmed.0020341.g002
Figure 2. Typical Deformity in a Patient with Leprosy 
(Photo: copyright WHO/P.Virot. This photo may not be reproduced for 
commercial purposes; see http://www.who.int/about/copyright/en/
index.html)
“We shall not be able to eliminate 
leprosy until we have a better 
understanding of its natural reservoir.”
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strategy should focus on integrating leprosy control activities 
into primary health care services, assuring early case 
detection, adequate chemotherapy, prevention of disability 
for all patients with nerve damage, and physical rehabilitation 
of those already disabled [12,17,18].
Work to dispel the stigma of leprosy and to introduce 
patients back into their communities must also be 
strengthened, experts note, in order to end social 
discrimination toward people with leprosy [18]. Leprosy 
remains a disease of the poor, although the exact social factors 
that put people at risk have not been identiﬁ  ed [19]. To break 
this link between leprosy and poverty, “leprosy should…now 
be included in the portfolio of diseases associated with 
poverty, and leprosy work incorporated into poverty reduction 
programmes,” points out Diana Lockwood of the London 
School of Hygiene and Tropical Medicine [20].
Lockwood and Suneetha have also suggested that the 
routine use of vaccination could beneﬁ  t the outcome of 
WHO’s anti-leprosy strategy [18]. Although the development 
of a speciﬁ  c and highly effective vaccine against leprosy is 
not yet a reality, the tuberculosis vaccine bacillus Calmette-
Guérin, made with live attenuated Mycobacterium bovis with 
the eventual addition of heat-killed M. leprae, has been 
proven to offer some immunity to leprosy. Its reported 
efﬁ  cacy ranges from 34% to 80% in different countries 
[2]. Despite this variable efﬁ  cacy, bacillus Calmette-Guérin 
vaccination is already widely used in leprosy-endemic 
countries—but who should be vaccinated, when, and 
how often in order to achieve maximal protection among 
the population are all a matter for debate [21]. Another 
promising intervention for leprosy prevention comes from 
a recent study, conducted on ﬁ  ve Indonesian islands, that 
found that giving people who are in close contact with 
patients with leprosy a short course of rifampicin can reduce 
their risk of developing the disease [22].
Finally, important research issues remain to be addressed. 
They include developing improved diagnostic tests and better 
ways to monitor and treat nerve damage, and understanding 
why MDT has not interrupted transmission [18]. “We shall 
not be able to eliminate leprosy until we have a better 
understanding of its natural reservoir,” says Donoghue. 
“There are several interesting reports that indicate that there 
may be an environmental reservoir for M. leprae—perhaps 
even in the soil in endemic regions.” Healthy human carriers 
also do exist, says Donoghue, who points out that by using 
sensitive molecular methods it is possible to detect the 
DNA from M. leprae in people who showed non-speciﬁ  c skin 
lesions and who had not been thought to have leprosy. Even 
after a ten-year MDT programme, more than 5% of healthy 
individuals in a leprosy-endemic area were positive for M. 
leprae DNA in their nasal passages, a recent study found, 
suggesting a high level of environmental contamination [23]. 
“Before anyone can talk about eliminating the disease we 
have to understand where the organisms are found, and the 
circumstances that result in an active infection,” Donoghue 
says.
Conclusion
It is widely believed that the leprosy elimination campaign has 
been a positive one. A comparably large consensus must now 
come together around the post-2005 leprosy agenda, to make 
sure that we do not lose the gains achieved to date or miss 
this unique opportunity to reach complete control of leprosy. 
Political, medical, or scientiﬁ  c disputes may have previously 
impeded unity among WHO and other stakeholders, but 
a reinforced partnership is now needed to continue the 
struggle to control and eradicate the disease.  
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